Full-Time
AI-driven healthcare data analysis platform
No salary listed
Senior, Expert
Company Historically Provides H1B Sponsorship
Remote in USA + 1 more
More locations: Philadelphia, PA, USA
Job can be performed in Philadelphia, PA or remotely.
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data, helping physicians make informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines AI with extensive research to provide tailored insights for both healthcare providers and drug developers, generating revenue through access to its platform and services.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.
Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision
Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.
Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.
Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.